Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study

[1] Huang C(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The Lancet 395 497-506

[2] Wang Y(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 323 1061-1069

[3] Li X(2020)Interleukin-6 in COVID-19: a systematic review and meta-analysis Rev Med Virol 30 1-9

[4] Ren L(2021)Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): a multicenter cohort study Int J Infect Dis 105 180-187

[5] Zhao J(2020)Do zinc supplements enhance the clinical efficacy of hydroxychloroquine? A randomized multicenter trial Biol Trace Elem Res 25 1-5

[6] Hu Y(2020)Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med 46 854-887

[7] Wang D(2019)Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update Critical Care Med 2021 E219-E234

[8] Hu B(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 384 693-704

[9] Hu C(2021)Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19 JAMA Intern Med 181 41-51

[10] Zhu F(2019)Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial BMJ 2021 372-9

[1] Huang C(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China The Lancet 395 497-506

[2] Wang Y(2020)Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China JAMA 323 1061-1069

[3] Li X(2020)Interleukin-6 in COVID-19: a systematic review and meta-analysis Rev Med Virol 30 1-9

[4] Ren L(2021)Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): a multicenter cohort study Int J Infect Dis 105 180-187

[5] Zhao J(2020)Do zinc supplements enhance the clinical efficacy of hydroxychloroquine? A randomized multicenter trial Biol Trace Elem Res 25 1-5

[6] Hu Y(2020)Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) Intensive Care Med 46 854-887

[7] Wang D(2019)Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update Critical Care Med 2021 E219-E234

[8] Hu B(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 384 693-704

[9] Hu C(2021)Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19 JAMA Intern Med 181 41-51

[10] Zhu F(2019)Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial BMJ 2021 372-9